NASDAQ: THARTharimmune Inc Stock Ownership - Who owns Tharimmune?
Insider buying vs selling
Have Tharimmune Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Sanam Parikh | Director | 2025-06-20 | 1,000 | $1.45 | $1.45kBuy |
| Sireesh Appajosyula | Chief Executive Officer | 2025-06-20 | 60,806 | $1.48 | $89.99kBuy |
| Sireesh Appajosyula | Chief Executive Officer | 2025-06-20 | 690 | $1.42 | $979.80Buy |
| Gravitas Capital LP | Executive Chairman | 2025-06-20 | 337,838 | $1.48 | $500.00kBuy |
| Sanam Parikh | Director | 2025-05-15 | 770 | $1.30 | $1.00kBuy |
| Randy Milby | CEO | 2024-12-19 | 4,600 | $2.12 | $9.75kBuy |
| Sireesh Appajosyula | Chief Operating Officer | 2024-11-13 | 5,000 | $2.02 | $10.10kBuy |
| Randy Milby | CEO | 2024-10-08 | 354 | $2.10 | $743.40Buy |
| Randy Milby | CEO | 2024-10-08 | 646 | $2.09 | $1.35kBuy |
| Randy Milby | CEO | 2024-10-08 | 1,500 | $2.09 | $3.13kBuy |
THAR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when THAR insiders and whales buy or sell their stock.
THAR Shareholders
What type of owners hold Tharimmune Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Highpoint Pharmaceuticals LLC | 36.54% | 972,222 | $1.68M | Insider |
| Kufe LLC | 30.46% | 810,395 | $1.40M | Insider |
| Gravitas Capital LP | 27.53% | 732,424 | $1.27M | Insider |
| Surender Kharbanda | 27.11% | 721,240 | $1.25M | Insider |
| Varinder Kaur | 24.54% | 653,059 | $1.13M | Insider |
| Sandeep Laumas | 23.90% | 636,008 | $1.10M | Insider |
| Leonard L. Mazur | 4.65% | 123,733 | $214.06k | Insider |
| Sireesh Appajosyula | 2.44% | 64,889 | $112.26k | Insider |
| Ubs Group Ag | 1.46% | 38,715 | $66.98k | Institution |
| Randy Milby | 0.66% | 17,534 | $30.33k | Insider |
THAR vs Biotech Stocks
Tharimmune Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.